Markets
PORTUGAL-HEALTH-MEDICINE-PHARMACEUTICAL-DRUGS-CANNABIS
(Patricia de Melo Moreira/Getty Images)

Tilray rises after reporting earnings, revenue beat

Tilray’s biggest areas of revenue growth have been its alcohol business and its international market.

J. Edward Moreno

Tilray rose in after-hours trading after it reported earnings results that beat Wall Street expectations, its first earnings report since President Trump signed an executive order directing regulators to reclassify marijuana as a less dangerous drug.

Tilray reported a loss per share of $0.02, compared to the $0.21 per-share loss analysts polled by FactSet were expecting. The company also reported $217.5 million in sales for the quarter ended November 30, higher than the $210.9 million the Street was penciling in.

The stock rose more than 5% in after-hours trading after the report came out. Its up 54% over the past six months.

Tilrays biggest areas of revenue growth have been its alcohol business and its international market. The company sold $20 million through its international segment, up from $14.8 million in the same period last year.

On December 18, Trump signed an executive order directing the attorney general to expedite the process of changing cannabis from a Schedule I drug, like heroin and LSD, to a Schedule III drug, like testosterone. The move would instantly make US cannabis companies more profitable by reducing their high tax burden.

Tilray does not sell adult-use cannabis in the US but still got a lift in its stock price amid the news, as it could potentially pave the way for the company to enter the market.

As the U.S. regulatory landscape progresses, Tilray is prepared to leverage its experience to play a key role in building a responsible, research-oriented national medical cannabis industry, Tilray CEO Irwin D. Simon said in a statement.

More Markets

See all Markets
markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.